Prostate cancer is the fifth leading cause of cancer-related deaths in males worldwide.1 While screening for prostate cancer may reduce prostate cancer–specific mortality, it comes at the risk of overdiagnosis, particularly in older males or those with comorbid medical conditions.2,3 Screening with serum prostate-specific antigen (PSA) in males who are unlikely to benefit from intervention for prostate cancer exposes these individuals to anxiety, invasive biopsies, and possible overtreatment, which could lead to unnecessary clinical consequences.4,5. The gene discussed is KLK3; the disease is cancer.